JAK2 and Alzheimer disease: Several STAT3 inhibitors, such as momelotinib, a novel JAK1/JAK2 inhibitor, and the JAK inhibitor JTE-052 downregulated the STAT3-specific signal, release of pro-inflammatory cytokines, total serum IgE levels, and mast cell numbers, and concomitantly improved the symptoms of AD (15, 42).